RxDoctor Payments Data

Katelynn Pannell, NP

Family · Tupelo, MSNPI 1013515667

Payments from drug & device makers

$5,597in general payments, 2019–2025

Across 227 payments — averaging $24.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$841
  • Dendreon Pharmaceuticals LLC$565
  • Myriad Genetic Laboratories, Inc.$437
  • Bayer$386
  • Astellas Pharma US Inc$379
  • Axonics, Inc.$329
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$5,48098%
  • Education$1172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,597 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$475,036
Medicare patients
1,087
Services billed
19,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron155$97,207
OrgovyxRelugolix17$46,011
MyrbetriqMirabegron84$45,213
Estradiol89$6,896
ErtapenemErtapenem Sodium13$6,685
Methenamine Hippurate100$5,268
Tamsulosin Hcl399$5,189
Doxycycline Hyclate230$2,893
Trospium Chloride37$2,649
Alfuzosin Hcl ErAlfuzosin Hcl119$1,735
Testosterone Cypionate36$1,211
Oxybutynin Chloride ErOxybutynin Chloride93$1,143
Finasteride86$1,137
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst46$1,128
Trimethoprim22$912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$841$143,218172 claims
Astellas Pharma US IncMyrbetriq$379$45,21384 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.

Other family in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →